Related Experiment Video
Updated: Mar 2, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Discordance Between HbA1c and Glucose Management Indicator in People With Type 2 Diabetes Treated With SGLT2
Akinori Hayashi1,2, Tomoaki Tsukushi3, Ryota Shinohara3
1Department of Fundamental Nursing, Kitasato University School of Nursing, Sagamihara, Japan.
Background:
The hemoglobin glycation index (HGI), defined as the difference between HbA1c and the glucose management indicator (GMI) derived from continuous glucose monitoring (CGM), has emerged as a tool to evaluate discordance between laboratory and sensor-based measures. The impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on these markers remains unclear.
Methods:
We retrospectively analyzed CGM data from 143 individuals with type 2 diabetes, stratified by SGLT2i use. Both HGI and glycated albumin-to-HbA1c (GA/HbA1c) ratio were compared. A restricted dataset (n = 117) excluding individuals with anemia or advanced renal dysfunction was also examined.
Results:
SGLT2i users exhibited higher hematologic parameters and significantly greater HGI (full dataset: 0.3 vs 0.1, P = .0297; restricted: 0.4 vs 0.1, P = .0206), whereas the GA/HbA1c ratio was significantly lower (full: 2.27 vs 2.54, P = .0117; restricted: 2.18 vs 2.38, P = .0178). The HbA1c-GMI relationship showed significantly different slopes between SGLT2i users and non-users, while the GA-GMI relationship was consistent across groups. Multivariate analyses identified SGLT2i use as an independent determinant of both higher HGI and lower GA/HbA1c ratio, even after adjustment for age, sex, body mass index (BMI), hemoglobin, albumin, renal function, mean glucose, and glycemic variability.
Conclusion:
SGLT2i therapy alters the interpretation of glycemic markers by elevating HGI and lowering GA/HbA1c, independent of hematologic and renal factors. These findings emphasize the need for individualized assessment of glycemic control using CGM-derived metrics and complementary biomarkers.
More Related Videos
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Dipeptidyl Peptidase 4 Inhibitors
Diabetes: Symptoms, Diagnosis, and Complications
Hypoglycemia and Glucagon
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...